Tsige Abate Wondesen, Beyene Dessale Abate
Department of Pharmacy, Asrat Woldeyes Health Science Campus Debre Berhan University Debre Berhan Ethiopia.
Health Sci Rep. 2024 May 30;7(6):e2149. doi: 10.1002/hsr2.2149. eCollection 2024 Jun.
Human papillomavirus (HPV) infections that continue to exist are the main cause of cervical cancer (CC), two-thirds of CC occurrences worldwide are caused by HPV 16 and HPV 18, and 99.7% of CC tumors are linked to oncogenic HPV infection. To identify challenges of CC and its prevention and treatment modalities.
This review examined the epidemiology, predisposing factors, genetic factors, clinical assessment methods, current treatment options, and prevention approaches for CC. We had perform a narrative data synthesis rather than a pooled analysis. A thorough literature search in pertinent databases related to CC was done with the inclusion of data that were published in the English language.
Early detection of CC is of utmost importance to detect precancerous lesions at an early stage. Therefore, all responsible agencies concerned with health should make all women aware of the benefits of CC screening and educate the general public. HPV vaccination coverage is very low in resource-limited settings.
To achieve the goal of eliminating CC as a public health problem in 2030, the World Health Organization will pay special attention to increasing HPV vaccination coverage throughout the world. To further improve HPV vaccine acceptability among parents and their children, safety-related aspects of the HPV vaccine should be further investigated through post-marketing surveillance and multicentre randomized clinical trials.
持续存在的人乳头瘤病毒(HPV)感染是宫颈癌(CC)的主要病因,全球三分之二的CC病例由HPV 16和HPV 18引起,且99.7%的CC肿瘤与致癌性HPV感染有关。旨在确定CC的挑战及其预防和治疗方式。
本综述研究了CC的流行病学、易感因素、遗传因素、临床评估方法、当前的治疗选择和预防方法。我们进行了叙述性数据综合分析而非汇总分析。在与CC相关的相关数据库中进行了全面的文献检索,纳入了以英文发表的数据。
CC的早期检测对于早期发现癌前病变至关重要。因此,所有相关的卫生责任机构应让所有女性了解CC筛查的益处并对公众进行教育。在资源有限的环境中,HPV疫苗接种覆盖率非常低。
为实现到2030年将CC作为公共卫生问题消除的目标,世界卫生组织将特别关注提高全球HPV疫苗接种覆盖率。为进一步提高家长及其子女对HPV疫苗的接受度,应通过上市后监测和多中心随机临床试验进一步研究HPV疫苗的安全性相关方面。